Back to News
research

Veradermics, Incorporated (MANE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Veradermics CEO Reid Waldman presented at the 2026 Leerink Global Healthcare Conference, highlighting the company’s focus on hair loss treatments—a chronic condition affecting 80 million people with significant psychological impact. The firm is developing an extended-release oral minoxidil tablet, originally a blood pressure drug repurposed for hair regrowth after Waldman observed its off-label use in dermatology journals. Waldman, a dermatologist, emphasized hair loss as the most prevalent dermatologic issue, driving demand for innovative solutions beyond topical treatments currently dominating the market. Veradermics aims to capitalize on minoxidil’s proven efficacy while improving compliance and reducing side effects through its extended-release formulation, addressing unmet patient needs. Analysts noted strong early interest in the company’s public debut, with Leerink Partners initiating coverage, signaling confidence in its pipeline and market potential.
AI Audio Summary
0:00 / 0:00
Click to play
f7e9219d-7515-46fb-86c9-f4778fc4627f.jpeg
Quantum News · Media Library

SA Transcripts159K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Veradermics, Incorporated (MANE) Leerink Global Healthcare Conference 2026 March 10, 2026 4:20 PM EDT Company Participants Reid Waldman - CEO & Director Conference Call Participants Marc Goodman - Leerink Partners LLC, Research Division Presentation Marc GoodmanLeerink Partners LLC, Research Division Okay. We're going to get going on our next session. Thanks for joining us. I'm Marc Goodman, one of the biopharma analyst at Leerink Partners, and we're lucky enough to have Veradermics with us, and we have the CEO, Reid Waldman. Thank you for joining us. Obviously, new company as being public entity. We started the coverage very recently, a story we like a lot, and it's really starting to resonate as we talk with people kind of live and everything. So anyway, thanks for joining us. Question-and-Answer Session Marc GoodmanLeerink Partners LLC, Research Division Maybe you can start with just how did you originate this idea? Where did it come from? And how did the company get going? Just give us a little sense of that first. Reid WaldmanCEO & Director Yes. So it's easy to be really excited about hair loss as a dermatologist, right? It is the single most prevalent chronic dermatologic condition, and it is a condition that essentially transcends being aesthetic, it's deeply personal, it's deeply psychological and it's essentially universal for our patients, affecting 80 million people. And so again, the ability to get excited about the market was very clear to us. I think the question becomes how did we get excited about developing a Minoxidil extended-release tablet? And I became familiar initially with off-label use of oral minoxidil when I was reviewing articles from the Journal of the American Academy of Dermatology. And I started using it off-label. But fundamentally, as I came to recognize, the drug is a blood pressure medication and the way

Read Original

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.